Vertex Pharmaceuticals upgraded to "neutral"
05/26/10 - Wedbush Morgan Securities
LONDON, May 26 (newratings.com) - Analysts at Wedbush Morgan upgrade Vertex Pharmaceuticals Incorporated (VRTX) from "underperform" to "neutral." The target price is set to $45.
Share Recommend this article to a friend add VRTX to my stocks and get e-mail alerts on Vertex Pharmaceuticals